Back to top
more

Editas Medicine (EDIT)

(Delayed Data from NSDQ)

$3.39 USD

3.39
1,628,393

-0.14 (-3.97%)

Updated Sep 25, 2024 04:00 PM ET

After-Market: $3.38 -0.01 (-0.29%) 6:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Add CRISPR Stock to Your Portfolio

by Zacks Equity Research

CRISPR Therapeutics (CRSP), a top-ranked stock at present, is developing its lead pipeline candidate to treat TDT and SCD.

US Government Assures Fund Accessibility to SVB (SIVB) Clients

by Zacks Equity Research

Following the collapse of Silicon Valley Bank (SIVB), the go-to bank for US tech startups, U.S. banking regulators step in to assure access to funds to the bank's customers, especially startups.

Editas (EDIT) Q4 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research

Editas (EDIT) reports a wider loss in the fourth quarter of 2022. The strategic reprioritization, announced last month, is expected to extend the company's cash runway into 2025.

Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of -4.76% and 43.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Alector (ALEC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Viatris' (VTRS) Q4 results are likely to be impacted by foreign exchange rate fluctuations. With the Biocon deal closed, investors await its impact on the 2023 guidance.

Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?

by Zacks Equity Research

Here is how Editas Medicine (EDIT) and Aspira (AWH) have performed compared to their sector so far this year.

Can Zymeworks (ZYME) Beat Expectations This Earnings Season?

by Zacks Equity Research

In the absence of a marketed product, Zymeworks (ZYME) is expected to provide an update on its pipeline candidates, mainly zanidatamab for the treatment of patients with HER2-expressing cancers, at the fourth-quarter conference call.

Does Editas (EDIT) Have the Potential to Rally 51.55% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 51.6% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

4 Biotech Stocks Set to Outpace Q4 Earnings Estimates

by Zacks Equity Research

Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Editas Medicine (EDIT) Crossed Above the 50-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Wall Street Analysts Predict a 72.25% Upside in Editas (EDIT): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Editas (EDIT) points to a 72.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Editas Medicine (EDIT) Crossed Above the 20-Day Moving Average: What That Means for Investors

by Zacks Equity Research

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Editas (EDIT) Moves Ahead With its Portfolio Reprioritization

by Zacks Equity Research

Editas (EDIT) enters into a deal with Shoreline Biosciences for licensing Editas proprietary gene editing technologies and cell franchise.

Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More

by Zacks Equity Research

Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.

Editas (EDIT) Dips on Portfolio Reprioritization, To Cut Jobs

by Zacks Equity Research

Editas (EDIT) enters a restructuring and portfolio reprioritization to focus on hemoglobinopathies and in vivo gene editing. The company is to reduce its workforce by almost 20%. Shares fall.

Editas (EDIT) Down 13.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why

by Zacks Equity Research

Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase I/II BRILLIANCE study on EDIT-101, treating Leber congenital amaurosis type 10.

Here's Why Editas (EDIT) Looks Ripe for Bottom Fishing

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Editas (EDIT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Editas (EDIT) Pauses Eye Disease Study on EDIT-101, Stock Down

by Zacks Equity Research

Editas (EDIT) pauses enrollment in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating blindness due to Leber congenital amaurosis 10. Stock falls.

Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus

by Zacks Equity Research

Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 6.90% and 99.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Viatris (VTRS) Q3 results are likely to be impacted by foreign exchange rate fluctuations. An update on the deal with Biocon is also expected along with the results.